Press Releases

DABRA Laser System Results Presented at 2019 NCVH Annual Conference

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE: RMED) Elias Kassab, MD, presented his successful experience using the DABRA laser system. “We have found that DABRA is successful in treating challenging lesions including long and severely calcified lesions, both above and below the knee.” The presentation was delivered on Wednesday, May 29, 2019, at the annual New Cardiovascular Horizons (NCVH) conference in New Orleans.

Dr. Kassab, FACC, FSCAI, FACP. FASA, RPVI, FAHA, FSVM, President & CEO of Michigan Outpatient Vascular Institute, Dearborn, Michigan, continued, “The device has an innate tendency to stay intraluminal in all vessels, is versatile as a single debulking device, is easy to use and is cost-effective. In our experience, DABRA has a very low complication rate and we have not seen any angiographic or clinical evidence of distal embolization.”

Dr. Kassab and Ashok Kondur, MD, recently reported that DABRA achieved a 98% lesion success rate in a 52-patient, single-center study that was summarized in the 2019 LINC Review. “Although these findings are from just 52 patients, they are very promising and strengthen the case for more extensive study of DABRA,” said Dr. Kassab.

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser system that non-thermally and photochemically ablates channels in vascular blockages. The technology reduces all plaque types into their fundamental chemistry, such as proteins, lipids, and other chemical compounds, eliminating blockages by dissolving them without generating potentially harmful particulates. Unlike many mechanical, acoustic, or thermal treatments for peripheral artery disease (PAD) that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma.

“DABRA quickly, safely, and efficiently restores blood flow, often in very difficult cases, enabling physicians to save patients’ limbs and lives,” added Dean Irwin, CEO, Ra Medical Systems.

For more information, please visit Ra Medical Systems at Booth No. 106 at NCVH or go to Each year, the NCVH annual conference assembles over 1,500 attendees and features live case transmissions, scientific lectures and faculty who are considered preeminent in the field of medicine.

About Ra Medical Systems

Ra Medical Systems is a commercial medical device company developing and marketing innovative excimer laser systems for the treatment of vascular and dermatologic diseases. DABRA launched in 2017 for the endovascular treatment of blockages resulting from lower extremity vascular disease and is CE marked for the indication of the endovascular treatment of infrainguinal arteries via atherectomy, and for crossing total occlusions. Pharos launched in 2004 for the treatment of dermatological disorders including psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra Medical’s core excimer laser technology platform that produces 308 nanometer light, a UVB wavelength that studies have demonstrated increases T-cell apoptosis, or cell death, which may produce a beneficial, targeted immunosuppressive effect. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Ra Medical's future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential benefits to patients and physicians using the DABRA catheter and laser system. Ra Medical's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the Company’s ability to effectually manage inventory; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical's business and operating results is contained in Ra Medical’s Quarterly Report on Form 10-Q for the quarter March 31, 2019 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (, our investor relations website (, press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Media Contacts
Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
212.896.1241 / 508.843.6428 /

Investor Contact
Jeffrey Kraws
President, Ra Medical Systems

Source: Ra Medical Systems, Inc.